申请人:EISAI R&D MANAGEMENT CO., LTD.
公开号:US20130203741A1
公开(公告)日:2013-08-08
A compound represented by the general formula:
or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C
6-14
aryl group or the like, L is —NR
e
CO— or the like (wherein R
e
is a hydrogen atom or the like), Ring B is a C
6-14
aryl group or the like, X is a C
1-3
alkylene group or the like, Y is a single bond or the like, Z is a C
1-3
alkylene group or the like, R
1
and R
2
are each independently a hydrogen atom or the like, and R
3
, R
4
, R
5
and R
6
are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.
一种化合物,其通式表示为:或其药学上可接受的盐或溶剂,其中环A为C6-14芳基或类似物,L为—NReCO—或类似物(其中Re为氢原子或类似物),环B为C6-14芳基或类似物,X为C1-3烷基或类似物,Y为单键或类似物,Z为C1-3烷基或类似物,R1和R2各自独立地为氢原子或类似物,而R3、R4、R5和R6各自独立地为氢原子、卤素原子或类似物。该化合物具有Aβ生成抑制作用或BACE1抑制作用,并可用作防治由Aβ引起的以阿尔茨海默病为代表的神经退行性疾病的预防或治疗剂。